Once‑weekly injection
Dual‑hormone; once‑weekly injection
Not FDA‑approved
Don’t fall for fakes. Follow the facts.
Before you buy, verify!
Quality You Can Trust vs. Gambles You Can't!
Your Health Deserves the Real Thing!
Don’t fall for fakes. Follow the facts.
Before you buy, verify!
Quality You Can Trust vs. Gambles You Can't!
Your Health Deserves the Real Thing!
GLP-1 receptor agonists mimic the gut hormone GLP-1, improving insulin secretion and slowing gastric emptying—effects that also reduce appetite and caloric intake. After years as type 2 diabetes drugs, they were studied and then authorized for chronic weight management in people with obesity or overweight plus a comorbidity. The first GLP-1 approved specifically for chronic weight management was liraglutide 3 mg (Saxenda) in Dec 2014. Source
Saxenda® (liraglutide 3 mg) — adult chronic weight management approved Dec 2014; adolescent indication (ages ≥12) added Dec 2020.
Wegovy® (semaglutide 2.4 mg) — adult chronic weight management approved June 2021; adolescent indication added Dec 2022; in Mar 2024, FDA added a landmark cardiovascular-risk-reduction indication for certain adults with overweight/obesity and established CVD.
Zepbound™ (tirzepatide) — approved Nov 8, 2023 for chronic weight management in adults; it activates GIP + GLP-1 receptors.
Wegovy (semaglutide 2.4 mg) is the obesity-dose version; Ozempic is semaglutide dosed for diabetes. Zepbound is tirzepatide for obesity; Mounjaro is tirzepatide for diabetes. (Same molecules, different brand names and labeled indications.) Zepbound is notable as a dual GIP/GLP-1 agonist.
Yes—in March 2024, the FDA approved Wegovy to reduce risk of major cardiovascular events (CV death, MI, stroke) in adults with CVD and overweight/obesity—the first weight-management drug with this claim, supported by the SELECT trial.
The FDA has cleared Saxenda (2020) and Wegovy (2022) for adolescents aged ≥12 with obesity.
The FDA has warned companies selling unapproved semaglutide/tirzepatide products marketed for human use. Stick to FDA-approved products and legitimate pharmacies.
Oct 2024:
FDA determined the tirzepatide shortage resolved, with short grace periods for compounders.
Feb 2025:
FDA determined the semaglutide shortage resolved and set grace periods to prevent treatment disruption.
April–May 2025:
Grace periods ended (503A pharmacies/physicians by April 22, 2025; 503B outsourcing facilities by May 22, 2025). After these dates, routine compounding of “essentially copies” of approved semaglutide/tirzepatide is no longer permitted.
Sept 2025:
FDA launched a “Green List” import alert to block illegal/poor‑quality GLP‑1 APIs from unverified foreign sources while allowing compliant API manufacturers.
Compounded GLP‑1s may only be prepared under narrow conditions (e.g., a specific medical need not met by an approved product).
Bulk API from unverified foreign suppliers can be detained at the border; products labeled “research use only/not for human use” are not appropriate for patients.
Using salt forms (e.g., semaglutide sodium/acetate) is not equivalent to approved drugs and should not be used for compounding.